Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Erenumab in migraine: indication of considerable added benefit for certain patients

2019-02-01 The first drug of a new drug class can reduce the number of headache days if other prophylactic medications have failed or have not been an option.

read more Link to \Erenumab in migraine: indication of considerable added benefit for certain patients\""

For the first time, IQWiG supported professional societies in the development of new S3 guideline

2019-01-31 Commissioned by the Federal Ministry of Health, the Institute searched for studies on vaginal (“natural”) birth and assessed them. The guideline group appreciates the high quality of the reports.

read more Link to \For the first time, IQWiG supported professional societies in the development of new S3 guideline\""

Advanced squamous cell carcinoma of the head and neck: Pembrolizumab prolongs survival

2019-01-15 Only few study participants received approval-compliant treatment. Therefore, the extent of added benefit is non-quantifiable.

read more Link to \Advanced squamous cell carcinoma of the head and neck: Pembrolizumab prolongs survival\""

In a nutshell 2018: New issue including facts and graphs from IQWiG

2019-01-09 The focus is on international HTA activities. Further topics: 7 years of AMNOG, big data, studies on medical devices, and other topics. Available online at IQWiG as a PDF or as a print version.

read more Link to \In a nutshell 2018: New issue including facts and graphs from IQWiG\""

Melanoma: dabrafenib and trametinib have added benefit

2019-01-02 This combination showed advantages in survival and recurrence. An added benefit was not proven for another combination used in advanced disease.

read more Link to \Melanoma: dabrafenib and trametinib have added benefit\""

Jens Flintrop to become new press officer at IQWiG

2018-12-12 From January 2019, Jens Flintrop will be Head of the Communications Unit. After many years as a journal editor, he became press officer at the Westfalen-Lippe Association of SHI Physicians.

read more Link to \Jens Flintrop to become new press officer at IQWiG\""

AMNOG as a learning system: New study on ingenol mebutate in actinic keratosis shows added benefit

2018-12-03 Following a negative G-BA decision due to a lack of data in 2013, the drug manufacturer now presented a suitable, albeit very short study.

read more Link to \AMNOG as a learning system: New study on ingenol mebutate in actinic keratosis shows added benefit\""

Balneo-phototherapy: Studies now show greater benefit also in atopic eczema

2018-11-22 For psoriasis, it has been known since 2007 that UV light therapy should be combined with brine baths. New data have now shown this also for atopic eczema.

read more Link to \Balneo-phototherapy: Studies now show greater benefit also in atopic eczema\""

Benefit of LDR brachytherapy in patients with early-stage prostate cancer is still unclear

2018-11-16 Even eleven years after the first benefit assessment, the evidence base remains inadequate. The hopes to be able to close gaps in knowledge were disappointed when PREFERE failed in 2016 due to a lack …

read more Link to \Benefit of LDR brachytherapy in patients with early-stage prostate cancer is still unclear\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

There are no actual comments.


Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Tildrakizumab (EU: Ilumetri, U.S.: Ilumya) for the treatment of psoriasis

Tildrakizumab (trade name EU: Ilumetri, U.S.: Ilumya) has been approved in Germany since September 2018 for the systemic treatment of moderate to severe plaque psoriasis in adults.   read more (Link to \Tildrakizumab (EU: Ilumetri, U.S.: Ilumya) for the treatment of psoriasis\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close